Product Description
Leading Justice is a full-service marketing company working with law firms on a cash-buy basis to sign up fully qualified, fraud-free firefighter foam cancer cases. Here at Leading Justice, we can customize your firm’s AFFF advertising needs and help you sign up cases via internal cash buys. Our clients only pay an agency fee to cover the cost of firefighter foam advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that doesn’t qualify for the target campaign is reviewed to determine whether it qualifies for another type of claim. By using advanced approaches to target contacts specifically related to firefighting foam and side effects like testicular cancer, prostate cancer, bladder cancer and pancreatic cancer, Leading Justice will increase your firm’s AFFF cancer caseload. If you are interested in helping victims of toxic firefighting foam exposure, our extensive consumer reach and direct advertising strategies at Leading Justice give you the competitive edge and confidence you need to allocate your full budget, knowing that your money is being used in the best way possible.
Each law firm we work with at Leading Justice plays an important role in determining how we classify claims as qualified or not. And while our experience working with plaintiff law firms allows us to recognize a great case when we see one, we will tailor our firefighter foam PFAS exposure intake specifications to the exact criteria you are seeking. So, if your firm has specific AFFF exposure qualifying case criteria you want us to use, we can train our intake specialists to apply the criteria to each email and phone call they receive. By getting rid of the middle man, Leading Justice offers clients an opportunity for internal cash buys of firefighting foam cancer data with no chance of fraud.
Firefighter Foam Exposure Litigation
Firefighting foam cancer lawsuits are being investigated on behalf of firefighters, U.S. military servicemembers, airport workers and others exposed to aqueous film forming foam (AFFF). Due to its superior ability to suppress jet fuel and petroleum fires, firefighter foam has been used in the United States for decades on U.S. military bases, by local fire departments, and at commercial airports and industrial sites. The reason AFFF offers superior suppression for fuel fires is because the foam contains per- and polyfluoroalkyl substances (PFAS), which have been identified by the EPA as “emerging contaminants” and have also been linked to adverse consequences for the environment and human health, including a possible increased risk of cancer. PFAS like perfluorooctane acid (PFOA) and perfluorooctanesulfonic acid (PFOS), both of which are present in AFFF, are persistent in the environment and the human body, meaning they don’t break down and can accumulate in blood and tissue over time, possibly leading to cancer or other negative health effects.
3M, Chemguard, Chemours and other manufacturers of AFFF are facing a growing number of lawsuits which accuse the companies of knowing about the potential for firefighter foam to cause cancer and harm the environment and continuing to manufacture, market and sell the products anyway, despite these risks. Attorneys across the country are investigating firefighting foam cancer claims on behalf of former and current firefighters, military personnel and airport workers who were exposed to toxic chemicals from using AFFF at work. Attorneys are also investigating cases in which individuals and families who live near locations where AFFF was used were diagnosed with cancer or suffered other serious side effects after being exposed to PFAS contamination in groundwater and drinking water supplies. According to a growing body of research, exposure to high concentrations of the chemicals in firefighter foam may increase the risk of testicular cancer, pancreatic cancer, prostate cancer, kidney cancer, bladder cancer, thyroid disease, lymphoma, leukemia and neuroendocrine tumors, among other adverse health effects. At least 500 lawsuits have already been consolidated in a multidistrict litigation (MDL) in South Carolina and additional claims are expected to be filed in the future.
